The Latest Breaking News from Big Pharma

Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.

As the United States recalibrates its trade policies to combat what the Trump administration sees as “unfair” treatment by other countries, two significant industries have complained to US regulators about their treatment in Australia.

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

A vaccine against tuberculosis has never been closer to reality. But development slowed due to corporate interests

Draft patent rules threaten pre-grant opposition, a key public health safeguard. Big pharma seeks to remove essential safeguards from India’s patent laws, creating needless hurdles in pre-grant opposition. Draft rules introduce variable fees, power to determine maintainability of representation by individuals/groups. This threatens access to quality-assured, affordable generics & extends…

Minnesota senator and anti-monopoly crusader explains how fixing Medicare's drug problem will help everybody